ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0702

Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing

Sarvar Nazir1, Lisa Rider2, Ira Targoff3, Stanley Naides4, Andrew Mammen5, Steven Greenberg6 and Adam Schiffenbauer5, 1NIEHS, NIH, Bethesda, MD, 2NIEHS, NIH, Garrett Park, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Self, Dana Point, CA, 5National Institutes of Health, Bethesda, MD, 6Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), dermatomyositis, Myositis, Pediatric rheumatology, prognostic factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients are important for diagnosis and prognosis. The currently accepted gold standards for autoantibody testing are time consuming and difficult to perform. Commercial testing may offer a more cost-effective and time-efficient method for autoantibody testing. However, the relative performance characteristics of commercial testing methods are not well known. We sought to determine the relative performance characteristics of autoantibody (Abs) testing from a widely-used commercial lab compared to gold standard methodologies.

Methods: Laboratory testing by protein and RNA immunoprecipitation (IP) and IP-immunoblotting methods performed by the Oklahoma Medial Research Foundation (OMRF) was used as the gold standard for anti-Jo1, OJ, EJ, PL-7, PL-12, Mi-2, SRP, Ku, MDA5, P155, PM/Scl, and MJ autoantibodies. Testing by ELISA and confirmation by IP in the Mammen laboratory was used as the gold standard for anti-HMGCR autoantibodies. Immunoblotting results from Mammen and Greenberg labs were used as gold standards for the CN1A autoantibody. Commercial antibody testing was performed on archived samples by a commercial lab using laboratory developed ELISAs for HMGCR and CN1A assays and a laboratory developed line blot method for the remaining autoantibodies. Up to 10 adults and juveniles positive by gold standard testing for each autoantibody were selected to be evaluated in the commercial lab.

Results: Samples from 198 patients with diagnosed IIM were used, of which 137 were adult and 61 were juvenile.

Across those autoantibodies with more than 5 gold standard positive (GSP) test results, sensitivities were greater than 0.95 for Jo1 (0.96, 22 GSP), EJ (1.0, 6 GSP), PL-12 (1.0, 10 GSP), and Ku (1.0, 8 GSP), and > 0.85 for Mi-2 (0.89, 9 GSP), MDA-5 (0.95, 19 GSP), and SRP (0.88, 20 GSP). PM/Scl (0.75, 8 GSP), MJ (0.74, 19 GSP), HMGCR (0.7, 10 GSP), P155 (0.48, 23 GSP), CN1A (0.37, 21 GSP), OJ (0, GSP) exhibited sensitivities under 0.85.

Two autoantibodies had specificities under 0.95: SRP (0.88) and Mi-2 (0.89). All other autoantibodies tested had a specificity above 0.95.

Subgroup analysis by age showed differences in sensitivity greater than 0.2 between CN1A Abs in adult (0.83) and juvenile IIM (0.15) (p = 0.004) and in anti-HMGCR Abs in adult (0.4) and juvenile IIM (0.15) (p = 0.038).

Conclusion: Of the autoantibodies with at least 5 positive gold standard positive results, there was a large variation in the sensitivities among the Abs. Sample storage may have impacted commercial test sensitivity. However, the specificities were strong overall. Our results show that commercial testing can be used as a tool for initial autoantibody testing in myositis patients, but the gold standards still provide value for autoantibody groups with low sensitivities, including P155, CN1A, and OJ. Further research is needed to explain sensitivity differences between age groups.


Disclosures: S. Nazir, None; L. Rider, Eli Lilly and Company, 12, Drug, CureJM, 1, Bristol Meyer Squibb, 5, Hope Pharmaceuticals, 5; I. Targoff, Oklahoma Medical Research Foundation Clinical Immunology Laboratory, 2, 5, UpToDate, 9; S. Naides, EUROIMMUN US, 2, 6, Applied BioCode, 2, Seegene Technologies, 12, Guidepoint, 1, Laboratory Corporation of America, 2, AlphaSights, 1; A. Mammen, None; S. Greenberg, None; A. Schiffenbauer, Hope Pharmaceuticals, 5, Quest Diagnostics, 5, Astrazeneca, 5.

To cite this abstract in AMA style:

Nazir S, Rider L, Targoff I, Naides S, Mammen A, Greenberg S, Schiffenbauer A. Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/performance-of-commercial-autoantibody-testing-in-comparison-to-recognized-gold-standards-in-myositis-autoantibody-testing/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-commercial-autoantibody-testing-in-comparison-to-recognized-gold-standards-in-myositis-autoantibody-testing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences